Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment
详细信息 查看全文
- 作者：Teresa Liu-Ambrose (1) (2)
Janice J Eng (1)
Lara A Boyd (1)
Claudia Jacova (3)
Jennifer C Davis (2) (4) (5)
Stirling Bryan (5)
Philip Lee (6)
Penny Brasher (5)
Ging-Yuek R Hsiung (3) - 刊名：BMC Neurology
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：10
- 期：1
- 全文大小：538KB
- 参考文献：1. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I: Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. / Neurology 2000,54(2):447鈥?51.
2. Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, / et al.: The cognitive syndrome of vascular dementia: implications for clinical trials. / Alzheimer disease and associated disorders 1999,13(Suppl 3):S21鈥?9.
3. Erkinjuntti T, Bowler JV, DeCarli CS, Fazekas F, Inzitari D, O'Brien JT, Pantoni L, Rockwood K, Scheltens P, Wahlund LO, / et al.: Imaging of static brain lesions in vascular dementia: implications for clinical trials. / Alzheimer disease and associated disorders 1999,13(Suppl 3):S81鈥?0.
4. Pantoni L, Leys D, Fazekas F, Longstreth WT Jr, Inzitari D, Wallin A, Filippi M, Scheltens P, Erkinjuntti T, Hachinski V: Role of white matter lesions in cognitive impairment of vascular origin. / Alzheimer disease and associated disorders 1999,13(Suppl 3):S49鈥?4.
5. Roman GC: Vascular dementia may be the most common form of dementia in the elderly. / Journal of the neurological sciences 2002, 203鈥?04:7鈥?0. CrossRef
6. Roman GC: Defining dementia: clinical criteria for the diagnosis of vascular dementia. / Acta neurologica Scandinavica 2002, 178:6鈥?. CrossRef
7. Boyle PA, Paul RH, Moser DJ, Cohen RA: Executive impairments predict functional declines in vascular dementia. / Clin Neuropsychol 2004,18(1):75鈥?2. CrossRef
8. Kovar M, Lawton M: Functional disability: Activities and instrumental activities of daily living. / Annu Rev Gerontol Geriatr 1994, 14:57鈥?5.
9. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K: Diabetes and the risk of stroke. The Honolulu Heart Program. / Jama 1987,257(7):949鈥?52. CrossRef
10. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR: Cardiovascular risk factors and cognitive decline in middle-aged adults. / Neurology 2001,56(1):42鈥?8.
11. Anstey KJ, Lipnicki DM, Low LF: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. / Am J Geriatr Psychiatry 2008,16(5):343鈥?54.
12. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. / Archives of internal medicine 2003,163(9):1069鈥?075. CrossRef
13. Middleton L, Kirkland S, Rockwood K: Prevention of CIND by physical activity: different impact on VCI-ND compared with MCI. / Journal of the neurological sciences 2008,269(1鈥?):80鈥?4. CrossRef
14. Cotman CW, Berchtold NC: Exercise: a behavioral intervention to enhance brain health and plasticity. / Trends in neurosciences 2002,25(6):295鈥?01. CrossRef
15. Adlard PA, Cotman CW: Voluntary exercise protects against stress-induced decreases in brain-derived neurotrophic factor protein expression. / Neuroscience 2004,124(4):985鈥?92. CrossRef
16. Dishman RK, Berthoud HR, Booth FW, Cotman CW, Edgerton VR, Fleshner MR, Gandevia SC, Gomez-Pinilla F, Greenwood BN, Hillman CH, / et al.: Neurobiology of exercise. / Scand J Med Sci Sports 2006,16(6):470. CrossRef
17. Adlard PA, Perreau VM, Pop V, Cotman CW: Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. / J Neurosci 2005,25(17):4217鈥?221. CrossRef
18. Moorhouse P, Rockwood K: Vascular cognitive impairment: current concepts and clinical developments. / The Lancet Neurology 2008,7(3):246鈥?55. CrossRef
19. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB: Vascular cognitive impairment. / The Lancet Neurology 2003,2(2):89鈥?8. CrossRef
20. Erkinjuntti T: Subcortical ischemic vascular disease and dementia. / International psychogeriatrics/IPA 2003,15(Suppl 1):23鈥?6. CrossRef
21. Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan DB, Feldman H, Ostbye T, Wolfson C, Gauthier S, Verreault R, / et al.: Progression of impairment in patients with vascular cognitive impairment without dementia. / Neurology 2001,57(4):714鈥?16.
22. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW: Research criteria for subcortical vascular dementia in clinical trials. / Journal of neural transmission 2000, 59:23鈥?0.
23. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O'Leary D, Fried L: Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. / Stroke; a journal of cerebral circulation 1996,27(8):1274鈥?282.
24. Manolio TA, Kronmal RA, Burke GL, Poirier V, O'Leary DH, Gardin JM, Fried LP, Steinberg EP, Bryan RN: Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. / Stroke; a journal of cerebral circulation 1994,25(2):318鈥?27.
25. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. / J Am Geriatr Soc 2005,53(4):695鈥?99. CrossRef
26. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. / J Psychiatr Res 1975,12(3):189鈥?98. CrossRef
27. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C: Galantamine treatment of vascular dementia: a randomized trial. / Neurology 2007,69(5):448鈥?58. CrossRef
28. Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS: Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. / Lancet neurology 2008,7(4):310鈥?18. CrossRef
29. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). / Stroke; a journal of cerebral circulation 2002,33(7):1834鈥?839.
30. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, Greenop KR, Almeida OP: Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease: A Randomized Trial. / JAMA 2008,300(9):1027鈥?037. CrossRef
31. Canadian Society for Exercise Physiology: / Par-Q and You. Gloucester, Ontario, Canada: Canadian Society of Exercise Physiology; 1994:1鈥?.
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. / Neurology 1994,44(12):2308鈥?314.
33. Washburn RA, Smith KW, Jette AM, Janney CA: The Physical Activity Scale for the Elderly (PASE): Development and evaluation. / Journal of clinical epidemiology 1993,46(2):153鈥?62. CrossRef
34. Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA: The physical activity scale for the elderly (PASE): Evidence for validity. / Journal of clinical epidemiology 1999,52(7):643鈥?51. CrossRef
35. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. / The American journal of psychiatry 1984,141(11):1356鈥?364.
36. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. / Lancet 2002,359(9314):1283鈥?290. CrossRef
37. Kemp PM, Holmes C, Hoffmann S, Wilkinson S, Zivanovic M, Thom J, Bolt L, Fleming J, Wilkinson DG: A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. / Journal of neurology, neurosurgery, and psychiatry 2003,74(11):1567鈥?570. CrossRef
38. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD: Donepezil in vascular dementia: a randomized, placebo-controlled study. / Neurology 2003,61(4):479鈥?86.
39. Ylikoski R, Jokinen H, Andersen P, Salonen O, Madureira S, Ferro J, Barkhof F, Flier W, Schmidt R, Fazekas F, / et al.: Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study. / Dementia and geriatric cognitive disorders 2007,24(2):73鈥?1.
40. Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the executive interview. / J Am Geriatr Soc 1992,40(12):1221鈥?226.
41. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. / Alzheimer disease and associated disorders 1997,11(Suppl 2):S33鈥?9.
42. Gotsman I, Stabholz A, Planer D, Pugatsch T, Lapidus L, Novikov Y, Masrawa S, Soskolne A, Lotan C: Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? / Isr Med Assoc J 2008,10(7):494鈥?98.
43. Enright PL, McBurnie MA, Bittner V, Tracy RP, McNamara R, Arnold A, Newman AB: The 6-min walk test: a quick measure of functional status in elderly adults. / Chest 2003,123(2):387鈥?98. CrossRef
44. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB: Lower-Extremity Function in Persons over the Age of 70 Years as a Predictor of Subsequent Disability. / The New England journal of medicine 1995,332(9):556鈥?62. CrossRef
45. Lord S, Sherrington C, Menz H: A physiological profile approach for falls prevention. In / Falls in older people Risk factors and strategies for prevention. Cambridge: Cambridge University Press; 2001:221鈥?38.
46. Lord SR, Menz HB, Tiedemann A: A physiological profile approach to falls risk assessment and prevention. / Phys Ther 2003,83(3):237鈥?52.
47. Neumann PJ, Goldie SJ, Weinstein MC: Preference-based measures in economic evaluation in health care. / Annual review of public health 2000, 21:587鈥?11. CrossRef
48. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C: The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. / Ann Rheum Dis 2004,63(4):395鈥?01. CrossRef
49. Borg G: Ratings of perceived exertion and heart rates during short-term cycle exercise and their use in a new cycling strength test. / Int J Sports Med 1982,3(3):153鈥?58. CrossRef
50. Persinger R, Foster C, Gibson M, Fater DC, Porcari JP: Consistency of the talk test for exercise prescription. / Medicine and science in sports and exercise 2004,36(9):1632鈥?636.
51. Foster C, Porcari JP, Anderson J, Paulson M, Smaczny D, Webber H, Doberstein ST, Udermann B: The talk test as a marker of exercise training intensity. / Journal of cardiopulmonary rehabilitation and prevention 2008,28(1):24鈥?0. quiz 31鈥?2
52. Schoenfeld D: Statistical considerations for pilot studies. / International journal of radiation oncology, biology, physics 1980,6(3):371鈥?74. CrossRef
53. Drummond M, Manca A, Sculpher M: Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. / International journal of technology assessment in health care 2005,21(2):165鈥?71.
54. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi H: Forecasting the global burden of Alzheimer's disease. / Alzheimer's and Dementia 2007, 3:186鈥?91. CrossRef
55. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/10/14/prepub - 作者单位：Teresa Liu-Ambrose (1) (2)
Janice J Eng (1)
Lara A Boyd (1)
Claudia Jacova (3)
Jennifer C Davis (2) (4) (5)
Stirling Bryan (5)
Philip Lee (6)
Penny Brasher (5)
Ging-Yuek R Hsiung (3)
1. Department of Physical Therapy, University of British Columbia, Vancouver, Canada
2. Centre for Hip Health and Mobility, Vancouver Coastal Research Institute, Vancouver, Canada
3. Division of Neurology, University of British Columbia, Vancouver, Canada
4. Experimental Medicine, University of British Columbia, Vancouver, Canada
5. Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Research Institute, Vancouver, Canada
6. Division of Geriatric Medicine, University of British Columbia, Vancouver, Canada
文摘
Background Sub-cortical vascular ischaemia is the second most common etiology contributing to cognitive impairment in older adults, and is frequently under-diagnosed and under-treated. Although evidence is mounting that exercise has benefits for cognitive function among seniors, very few randomized controlled trials of exercise have been conducted in populations at high-risk for progression to dementia. Aerobic-based exercise training may be of specific benefit in delaying the progression of cognitive decline among seniors with vascular cognitive impairment by reducing key vascular risk factors associated with metabolic syndrome. Thus, we aim to carry out a proof-of-concept single-blinded randomized controlled trial primarily designed to provide preliminary evidence of efficacy aerobic-based exercise training program on cognitive and everyday function among older adults with mild sub-cortical ischaemic vascular cognitive impairment. Methods/Design A proof-of-concept single-blinded randomized trial comparing a six-month, thrice-weekly, aerobic-based exercise training group with usual care on cognitive and everyday function. Seventy older adults who meet the diagnostic criteria for sub-cortical ischaemic vascular cognitive impairment as outlined by Erkinjuntti and colleagues will be recruited from a memory clinic of a metropolitan hospital. The aerobic-based exercise training will last for 6 months. Participants will be followed for an additional six months after the cessation of exercise training. Discussion This research will be an important first step in quantifying the effect of an exercise intervention on cognitive and daily function among seniors with sub-cortical ischaemic vascular cognitive impairment, a recognized risk state for progression to dementia. Exercise has the potential to be an effective, inexpensive, and accessible intervention strategy with minimal adverse effects. Reducing the rate of cognitive decline among seniors with sub-cortical ischaemic vascular cognitive impairment could preserve independent functioning and health related quality of life in this population. This, in turn, could lead to reduced health care resource utilization costs and avoidance of early institutional care. Trial Registration ClinicalTrials.gov Protocol Registration System: NCT01027858.